[go: up one dir, main page]

AU2002356352A1 - Use of 5-chloro-4-(3-(n-(2-(3,4-dimethoxy-phenyl)-ethyl)-n-methylamino)-propylamino)-3-(2h)-pyridazinone as metabolic modulator - Google Patents

Use of 5-chloro-4-(3-(n-(2-(3,4-dimethoxy-phenyl)-ethyl)-n-methylamino)-propylamino)-3-(2h)-pyridazinone as metabolic modulator

Info

Publication number
AU2002356352A1
AU2002356352A1 AU2002356352A AU2002356352A AU2002356352A1 AU 2002356352 A1 AU2002356352 A1 AU 2002356352A1 AU 2002356352 A AU2002356352 A AU 2002356352A AU 2002356352 A AU2002356352 A AU 2002356352A AU 2002356352 A1 AU2002356352 A1 AU 2002356352A1
Authority
AU
Australia
Prior art keywords
pyridazinone
propylamino
methylamino
dimethoxy
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002356352A
Inventor
Laszlo Gabor Harsing
Katalin Ivanicsne Megyeri
Gyorgy Levay
Aniko Miklosne Kovacs
Ildiko Nagyne Gyonos
Maria Szecseyne Hegedus
Gabor Szenasi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egis Pharmaceuticals PLC
Original Assignee
Egyt Gyogyszervegyeszeti Gyar
Egis Pharmaceuticals PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egyt Gyogyszervegyeszeti Gyar, Egis Pharmaceuticals PLC filed Critical Egyt Gyogyszervegyeszeti Gyar
Publication of AU2002356352A1 publication Critical patent/AU2002356352A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002356352A 2002-09-11 2002-12-28 Use of 5-chloro-4-(3-(n-(2-(3,4-dimethoxy-phenyl)-ethyl)-n-methylamino)-propylamino)-3-(2h)-pyridazinone as metabolic modulator Abandoned AU2002356352A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP0202993 2002-09-11
HU0202993A HU227181B1 (en) 2002-09-11 2002-09-11 Use of 5-chloro-4-[3-[n-[2-(3,4-dimethoxyphenyl)ethyl)]-n-methylamino]-propylamino]-3-(2h)-pyridazinone for producing pharmaceutical compositions having metabolic modulator effect
PCT/HU2002/000172 WO2004024158A1 (en) 2002-09-11 2002-12-28 Use of 5-chloro-4-[3-[n-[2-(3,4-dimethoxy-phenyl)-ethyl]-n-methylamino]-propylamino]-3-(2h)-pyridazinone as metabolic modulator

Publications (1)

Publication Number Publication Date
AU2002356352A1 true AU2002356352A1 (en) 2004-04-30

Family

ID=89980763

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002356352A Abandoned AU2002356352A1 (en) 2002-09-11 2002-12-28 Use of 5-chloro-4-(3-(n-(2-(3,4-dimethoxy-phenyl)-ethyl)-n-methylamino)-propylamino)-3-(2h)-pyridazinone as metabolic modulator

Country Status (3)

Country Link
AU (1) AU2002356352A1 (en)
HU (1) HU227181B1 (en)
WO (1) WO2004024158A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU214320B (en) * 1991-12-20 1998-03-02 EGIS Gyógyszergyár Rt. Process for the preparation of novel 3 (2H) -pyridazinone derivatives and pharmaceutical compositions containing them
HUP0103064A3 (en) * 2001-07-26 2005-06-28 Egis Gyogyszergyar Nyilvanosan Polymorphic form of 5-chloro-4-(3-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino]-propylamino)-3-(2h)-piridazinone fumarate, its use, process for its preparation and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
HU0202993D0 (en) 2002-11-28
HU227181B1 (en) 2010-09-28
HUP0202993A3 (en) 2004-10-28
WO2004024158A1 (en) 2004-03-25
HUP0202993A2 (en) 2004-06-28

Similar Documents

Publication Publication Date Title
AP1660A (en) Crystals including a malic acid salt of N - [2 -(diethylamino) ethyl] - 5 - [ (5 - fluoro -2-oxo - 3H -indole -3 - ylidene) methyl] - 2,4 - dimethyl - 1H- pyrrole -3 -carboxamide, processes for its preparation and compositions thereof.
AP2003002836A0 (en) 3-(4-Amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors.
DK1353917T3 (en) New Process for the Synthesis of 5- (4-Fluorophenyl) -1- [2 - ((2R, 4R) -4-hydroxy-6-oxo-tetrahydro-pyran-2-yl) ethyl] -2-isopropyl-4 -phenyl-1H-pyrrole-3-carboxylic acid phenylamide
SI1870100T1 (en) Ethyl 3-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-2-pyridylamino)propionate methansulfonate
AU2003257437A1 (en) Novel 2,5-disubstituted pyrimidine derivatives
AU2003259252A1 (en) Antisense modulation of polo-like kinase expression
WO2003047520A3 (en) SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS
AU2003269885A1 (en) Antisense modulation of g protein-coupled receptor kinase 6 expression
ZA974912B (en) Salts of ethyl 3-(2-(4-(4-(amino-imino-methyl)phenyl)-4-methyl-2,5-dioxo-imidazolidin-1-yl)acetylamino)-3-phenyl-propionate.
EP1716134A4 (en) AMINO HETEROCYCLIC COMPOUNDS MODULATING CHEMOKINE RECEPTOR ACTIVITY
IS2473B (en) Composition containing N- (3-methoxy-5-methylpyrazin-2-yl) -2- (4- (1,3,4-oxadiazol-2-yl) phenyl) pyridine-3-sulfonamide (ZD4054), or pharmaceutically its recognized salt, and EGFR TKI, or its pharmaceutically acceptable salt
PL1632232T3 (en) Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
AU2002356352A1 (en) Use of 5-chloro-4-(3-(n-(2-(3,4-dimethoxy-phenyl)-ethyl)-n-methylamino)-propylamino)-3-(2h)-pyridazinone as metabolic modulator
AU2003215158A1 (en) 2-(5-(5-carbamimidoyl-1h-heteroaryl))-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors
AU2002253222A1 (en) Dyeing compositions for the dyeing of keratin fibres, comprising heterocyclic hydrazone compounds
AU2002354850A1 (en) 4-(benzylidene-amino)-3-(methylsulfanyl)-4H-(1, 2, 4) triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies
TW200612944A (en) 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-(substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors
AU2001290743A1 (en) Solid salt forms of n-(2-(4-(2-(1-methylethoxy)phenyl)-1-piperazinyl)ethyl)-2-oxo-1-piperidineacetamide
HUP0103064A3 (en) Polymorphic form of 5-chloro-4-(3-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino]-propylamino)-3-(2h)-piridazinone fumarate, its use, process for its preparation and pharmaceutical compositions containing it
AU2003297554A1 (en) Modulation of death-associated protein kinase 1 expression
AU4595100A (en) ((e),3(r))-enantiomer of 4-(3-chloro -4-cyanophenyl) -1-(p- methylsulphonyl -phenylsulphonyl) -2-trifluoromethylbut -trans-3-en-ol
AU1572201A (en) Crystalline salts of (S)-4-(3-(N-(2-(4-(5-carbamoyl-2-pyridyloxy)phenyl)-1,1- dimethylethyl)amino)-2-hydroxypropoxy)indole
NO20002837D0 (en) New arylpiperazinylalkyl-3 (2H) -pyridazinones
AU2002343329A1 (en) 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
AU2002254271A1 (en) Novel salt and crystalline forms of (2r)-anti-5-{3-(4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl)-2-hydroxypropoxy}quinoline

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase